3. Rocket Pharmaceuticals (NASDAQ:RCKT)
Rocket Pharmaceuticals takes the No. 3 spot because it has already crossed a major regulatory line that many biotech companies never reach. Trading around $3.07 with a market capitalization of about $344 million, RCKT is a small-cap gene therapy stock with an FDA accelerated approval already in hand for KRESLADI, the first gene therapy for severe LAD-I. That alone makes it one of the more important biotech penny stocks to watch this June.
The FDA accelerated approval for KRESLADI gives Rocket a level of credibility that many clinical-stage biotech companies still lack. Severe LAD-I is an ultra-rare disease, which means the commercial market is not massive by patient count. But in rare disease biotechnology, small patient populations can still matter because treatments may command high value, regulatory incentives can be meaningful, and successful execution can validate the company’s platform.
Another key part of the story is the Rare Pediatric Disease Priority Review Voucher. For biotech investors, a PRV can be valuable because it may be sold or used to speed review of another drug application. That gives Rocket additional optionality beyond the product itself. In a $300 million-plus biotech company, an FDA-approved gene therapy plus a PRV creates a stronger foundation than the typical penny-stock biotech setup.
The risk is commercial uptake. Ultra-rare disease therapies can be scientifically impressive but commercially limited. Investors need to see whether the product can reach the right patients, whether treatment centers can support adoption, and whether revenue can become meaningful enough to justify a stronger valuation. In rare disease biotech, execution is often just as important as approval.
Still, Rocket’s ranking is deserved. Gene therapy remains one of the most closely watched areas in biotech investing because it aims to treat diseases at their genetic root. The field is complex, costly, and risky, but it can also create major value when a company proves that its platform works. RCKT now has an FDA-approved asset, and that is a major differentiator among biotech stocks under $5.
For investors searching for “best gene therapy penny stocks,” “rare disease biotech stocks,” “FDA-approved biotech penny stocks,” and “NASDAQ biotech stocks to buy in June,” Rocket Pharmaceuticals stands out as one of the more credible names. It is still risky, but it has already achieved something meaningful.
Click next to see the following stock...
